

HB1225\_L.015

SENATE COMMITTEE OF REFERENCE AMENDMENT

Committee on Health & Human Services.

HB23-1225 be amended as follows:

- 1 Amend reengrossed bill, page 4, strike lines 25 to 27 and substitute:
- 2       "(b) A biosimilar drug that has an initial wholesale acquisition
- 3 cost that is not at least fifteen percent lower than the corresponding
- 4 biological product. ~~or~~".

\*\* \*\* \*\* \*